August 26, 2022

August 26, 2022

It’s Not Over Yet: The Ongoing Impact of COVID-19 for Those with CLL/SLL

Infectious disease specialist, Dr. Shmuel Shoham, will briefly present some of the newest clinical updates and guidance, with the remainder of the event being dedicated to answering audience questions about COVID-19 and CLL/SLL.

August 26, 2022

Elisabeth Wright Shares Her Journey with CLL

Eight years ago this month, I was diagnosed with chronic lymphocytic leukemia (CLL). My world turned upside down. I knew nothing about CLL but had to get smart on the subject. And I did this with the help of good doctors and organizations such as the CLL Society.

August 26, 2022

Dr. Brian Koffman Shares His Experience Receiving Evusheld with ASPR to Increase Awareness and Access Across Healthcare Practices in the United States

CLL Society believes that every immunocompromised individual, including those with chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL), regardless of treatment status, should experience easy access to the life-saving pre-exposure prophylaxis therapy or PreP, Evusheld.

August 26, 2022

ASH 2021: Dr. Stephan Stilgenbauer on Venetoclax-Based Time-Limited Combination Treatments for Chronic Lymphocytic Leukemia (CLL)

At the annual meeting of the American Society of Hematology (ASH) 2021, our own Dr. Brian Koffman, interviewed Dr. Stephan Stilgenbauer, Professor of Medicine at the Comprehensive Cancer Center at Ulm University in Germany. They discussed the latest results from the GAIA (CLL13) trial, which compared rates of measurable

August 26, 2022

ASH 2021: Phase 1/2 Trial of IL7/IL15-Expanded Bispecific LV20.19 CAR T-Cells for Relapsed, Refractory B-Cell Non-Hodgkin Lymphoma

These results are encouraging and show that patients with relapsed/refractory B-cell NHL treated with bispecific LV20.19 CAR T-cells have a high overall response rate and low rates of grade ≥3 CRS or ICANS.

Cookie	Duration	Description
cookielawinfo-checkbox-analytics	11 months	This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Analytics".
cookielawinfo-checkbox-functional	11 months	The cookie is set by GDPR cookie consent to record the user consent for the cookies in the category "Functional".
cookielawinfo-checkbox-necessary	11 months	This cookie is set by GDPR Cookie Consent plugin. The cookies is used to store the user consent for the cookies in the category "Necessary".
cookielawinfo-checkbox-others	11 months	This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Other.
cookielawinfo-checkbox-performance	11 months	This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Performance".
viewed_cookie_policy	11 months	The cookie is set by the GDPR Cookie Consent plugin and is used to store whether or not user has consented to the use of cookies. It does not store any personal data.

August 26, 2022

It’s Not Over Yet: The Ongoing Impact of COVID-19 for Those with CLL/SLL

Elisabeth Wright Shares Her Journey with CLL

Dr. Brian Koffman Shares His Experience Receiving Evusheld with ASPR to Increase Awareness and Access Across Healthcare Practices in the United States

ASH 2021: Dr. Stephan Stilgenbauer on Venetoclax-Based Time-Limited Combination Treatments for Chronic Lymphocytic Leukemia (CLL)

ASH 2021: Phase 1/2 Trial of IL7/IL15-Expanded Bispecific LV20.19 CAR T-Cells for Relapsed, Refractory B-Cell Non-Hodgkin Lymphoma

CLL SOCIETY FAST FIND

QUICK LINKS

ABOUT US

CONTACT